Lung Cancer Pathophysiology: An Interdisciplinary Approach

✍ Scribed by Nima Rezaei (editor)

• Publisher: Springer
• Year: 2024
• Tongue: English
• Leaves: 272
• Series: Interdisciplinary Cancer Research; 8
• Category: Library

✦ Table of Contents

Preface
Contents
About the Editor
Interdisciplinary Approach in Lung Cancers
1 Introduction
2 Epidemiology
3 Screening
4 Clinical Manifestations and Diagnosis
5 Classification
6 Treatment
7 Conclusion
References
Fundamental Elements of a High-Functioning Lung Cancer Multidisciplinary Team (MDT)
1 Introduction
1.1 Multidisciplinary Team
1.2 Leadership
1.3 Team Collaboration
1.4 The MDT Venue
1.5 Data
1.6 MDT Billing
1.7 Biobank
1.8 Research
2 Conclusion
References
Epithelial to Mesenchymal Transition in Lung Cancer: When It Starts?
1 Introduction: EMT in Early-Stage Lung Cancer
2 EMT Phenotype in Early-Stage Lung Cancer
2.1 Regulatory Genes of EMT in Early-Stage Lung Cancer
2.2 Circulating Tumor Cells in Early-Stage EMT in Lung Cancer
2.3 Lymph Node Status and Phenotypic Transition in Early-Stage EMT
3 The Roles of ncRNA in EMT Regulation in Early-Stage Lung Cancer
3.1 miRNAs in EMT Regulation in Lung Cancer
3.2 lncRNAs in EMT in Early-Stage Lung Cancer
4 EMT as Mechanisms of Resistance to Conventional and Targeted Therapies in Lung Cancers: Correlations with Different Treatmen...
4.1 Adjuvant Treatment Setting as a Potential Early Time Point for EMT
4.2 First-Line Treatment of Advanced and Metastatic Lung Cancer Harboring Actionable Mutations as a Potential Early Time Point...
5 Conclusion
References
Roles of Tumor Immune Microenvironment in Non-small Cell Lung Cancer
1 Introduction
2 Interaction Between Tumor and TIME
2.1 Tumor Intrinsic Factors
2.1.1 Immunogenic Hot Tumors
2.1.2 Immunosuppressive Cold Tumors
2.1.3 Premalignant Lesions
2.2 Immune Contexture
2.2.1 T Lymphocytes
2.2.2 B Lymphocytes
2.2.3 Natural Killer Cells
2.2.4 Macrophages
2.2.5 Neutrophils
2.2.6 Dendritic Cells
2.2.7 Myeloid-Derived Suppressor Cells (MDSCs)
3 Tertiary Lymphoid Structures (TLSs)
4 TNM-I: TNM-Immunoscore in NSCLC
4.1 Location and Compartments of Immune Cells Within the Tumor
4.2 Scoring Method: Manual or Digital?
4.3 Whole Slides or Tissue Microarrays
5 Conclusion
References
Natural Killer Cells in Lung Cancer
1 Introduction
1.1 Non-small-cell Lung Cancer
1.2 Small-Cell Lung Cancer
2 Natural Killer Cells
2.1 Development and Maturation
2.2 NK Cell Cytotoxicity
3 Natural Killer Cells and Lung Cancer
3.1 NK Cell-Based Immunotherapies in Lung Cancer
4 Conclusion
References
RNA-binding Proteins as a New Link Between COPD and Lung Cancer
1 Introduction
2 RNA-binding Proteins (RBPs) as Mediator of Post-transcriptional Gene Regulation (PTGR)
3 RBPs in COPD Pathogenesis
4 RBPs in Modulating the Inflammation of Lower Airways
5 RBPs in Modulating IL-33 Signaling Pathway and COPD
6 RBPs in Modulating Drugs Response in COPD
7 RBPs in Lung Cancer Pathogenesis
8 Non-small Cell Lung Cancer (NSCLC)
9 Small Cell Lung Cancer (SCLC)
10 RBPs in Modulating IL-33 Signaling Pathway and Lung Cancer
11 The Role of RBPs in Mechanisms Linking COPD and Lung Cancer
12 Conclusion
References
The Implication of miRNA Signature in the Characteristic Features and Diagnosis of Lung Cancer
1 Introduction
1.1 Lung Cancer
1.2 MicroRNA
1.3 Biogenesis of miRNA
2 Impact of miRNA Signatures in Targeting the Various Characteristics of LC
2.1 Sustaining Proliferative Signaling in LC
2.2 Evading Growth Suppressors in LC
2.3 Resisting Cell Death in LC
2.4 Enabling Replicative Immortality in LC
2.5 Inducing Angiogenesis
2.6 Activating Invasion and Metastasis in LC
2.7 Deregulating Cellular Energetic in LC
2.8 Avoiding Immune Destruction in LC
2.9 Tumor-Promoting Inflammation
2.10 Genome Instability and Mutation
3 MicroRNA as Diagnostic Markers in LC
3.1 Biomarkers
3.2 miRNA as Noninvasive Diagnostic Markers
3.3 miRNA as Biomarker in Histological Subtype Identification
3.4 miRNA as a Biomarker in the Differentiation of Tumors
4 Conclusion and Perspectives
References
MicroRNAs in the Immunopathology and Treatment of Non-small Cell Lung Cancer
1 Introduction
1.1 Statistics of NSCLC
2 sncRNAs in Development of NSCLC
3 sncRNAs as Markers of Efficacy of Treatment
4 Surgery
5 Radiotherapy
6 Chemotherapy
6.1 Platinum Derivatives
6.2 Taxanes
7 Immune Therapy
7.1 Immunopathology of NSCLC
7.2 EGFR
7.3 PD/PD-L1
7.4 CTLA-4
8 MicroRNA-Based Therapy
8.1 Application Schemas
9 Side Effects and Complications
9.1 Conventional Therapy
9.2 MicroRNA-Based Therapy
10 Conclusion
References
Monitoring Exosomal Non-coding RNA in Lung Cancers
1 Introduction
2 Non-coding RNAs
2.1 MicroRNAs
2.2 Long Non-coding RNAs
3 Exosomes
3.1 Exosome Biogenesis
3.2 Exosomes Cargo
3.3 Exosomes in Cancer
4 Non-coding RNAs as Biomarkers in Lung Cancer
4.1 Exosome-Derived miRNAs and Lung Cancer Proliferation
4.2 Exosome-Derived miRNAs and Angiogenesis
4.3 Exosome-Derived ncRNAs and EMT/MET
4.4 Exosomal miRNAs Underlying Cisplatin Resistance
5 Exosome-Derived miRNAs and Their Diagnostic and Clinical Relevance
6 Conclusion
References
Mediastinal Staging of Lung Cancer
1 Introduction
2 Imaging Techniques
3 Non-surgical Techniques: Diagnostic Procedures in Interventional Pulmonology
3.1 Transbronchial Needle Aspiration
3.2 Endobronchial Ultrasound-TBNA
3.3 Esophageal Ultrasound-Guided Fine Needle Aspiration
3.4 EBUS-TBNA and EUS-FNA Technique
3.5 Samples
3.6 Safety and Contraindications
3.7 Use of Combination Techniques
3.8 Transthoracic Needle Aspiration
3.9 Lymph Node Cryobiopsy
3.10 Rapid On-Site Evaluation
3.11 Endobronchial Elastography
4 Surgical Techniques
4.1 Mediastinoscopy
4.2 Transcervical Extended Mediastinal Lymphadenectomy
4.3 Video-Assisted Mediastinoscopic Lymphadenectomy
4.4 Video-Assisted Thoracic Surgery
4.5 Robotic-Assisted Thoracic Surgery
5 Restaging After Oncologic Therapy
5.1 Imaging
5.2 EBUS-TBNA
5.3 Surgical Techniques
6 Restaging After Surgery
7 Conclusion and Future Perspectives
References
Pleural Mesothelioma: The Importance of Working Together
1 Introduction
2 Histopathological Classification
3 Genetic Mutations
4 Gene Expression Modulation
5 Diagnosis
6 Treatment
7 The Importance of Working Together
References
Comprehensive Genomic Profiling in Lung Cancer in the Era of Immunotherapy Approaches: The Role of Molecular Tumour Boards
1 Introduction
2 Efficacy of Immunotherapy in Advanced NSCLC Patients Harbouring EGFR Mutations or ALK Rearrangement
3 Efficacy of Immunotherapy in Advanced NSCLC Patients Harbouring Rare Oncogenic-Driven Alterations: The IMMUNOTARGET Registry
4 The Role of Molecular Tumour Boards: Experiences, Strengths and Limits
5 Conclusion
References
Index